PRINCETON, N.J. — The Food and Drug Administration has approved a branded acne drug made by Ranbaxy Labs, the drug maker said.
Ranbaxy announced the FDA approval of Absorica (isotretinoin), a drug for treating severe recalcitrant nodular acne. The company expects to launch Absorica in the United States in fourth quarter 2012 under an agreement with Canada-based Cipher Pharmaceuticals.
"We are thrilled to make Absorica available as a valuable option for the dermatologist and patients who need treatment for severe recalcitrant nodular acne," Ranbaxy SVP and regional director for the Americas Venkat Krishnan said. "Absorica is a critical milestone in our commitment to serve the dermatology community and will be the flagship brand for Ranbaxy's specialized dermatology sales force."